相关实验视频

Updated: Jun 27, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

高复杂的数字空间概况识别了与Everolimus和Letrozole治疗激素受体-阳性/人表皮生长因子受体2-阴性先进乳腺癌的反应和生存相关的益生素诱导蛋白mRNA

Yuhang Han¹, Danyang Ji¹, Yujing Tan¹

¹Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.

|December 1, 2025

概括

在晚期乳腺癌中需要预测性生物标志物来检测常 (EVE). 益生素诱导蛋白 (PIP) 的mRNA表达和免疫性特征可以识别患者对EVE有抗性,这表明PIP是潜在的预测生物标志物.

科学领域:

在瘤学瘤学.
翻译研究是翻译研究.
生物标志物发现发现

背景情况:

联合莱特醇的Everolimus (EVE) 是一种已批准的治疗激素受体阳性/人体表皮生长因子受体2-阴性 (HR+/HER2-) 晚期乳腺癌 (ABC) 的治疗方法.
在ABC中EVE疗效的预测生物标志物仍未定义.
数字空间分析 (DSP) 提供了一种探索瘤微环境的方法,用于预测标记.

研究的目的:

在HR+/HER2-ABC中使用DSP识别EVE疗效的预测生物标志物.
调查与对EVE加莱特醇治疗的反应或耐药性相关的免疫和转录基因标记物.
评估PIP mRNA作为预测生物标记物的潜力.

主要方法:

2期MIRACLE试验数据来自21名HR+/HER2-ABC患者,这些患者接受了EVE加乐治疗.
预处理瘤样本的数字空间分析 (DSP).
分析瘤,白细胞和肌瘤区间内的免疫和转录基因标记物.

主要成果:

响应者显示出更高的纤维细胞透率,而非响应者则增加了中性粒细胞.
在非响应者中,益生菌诱导蛋白 (PIP) mRNA表达显著增加.
增加的PIP mRNA表达与EVE耐药性和不良的无进展生存率 (PFS) 相相关.

结论:

特定的免疫瘤特征和PIP mRNA表达与HR+/HER2-ABC中对EVE的抵抗有关.
PIP mRNA显示出作为患者分层的空间解析预测生物标志物的潜力.
进一步验证PIP可以帮助优化晚期乳腺癌的EVE治疗策略.

关键词:

HR+/HER2− 是晚期乳腺癌.这就是PIP mRNA.这是Everolimus.高复杂的数字空间配置文件.莱特罗斯 (Letrozole) 是一种可靠的药物.

更多相关视频

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...